HIV-1 vaccines: challenges and new perspectives

Area of Science:

• Immunology
• Vaccinology
• Public Health

Background:

• Preventive HIV-1 vaccine development is a critical global health objective.
• Previous vaccine trials faced challenges but have yielded valuable insights.
• Recent advancements include proof-of-concept efficacy and identification of immune correlates of risk.

Purpose of the Study:

• To summarize the current state and future directions of HIV-1 vaccine development.
• To highlight key findings from recent clinical trials, including immune correlates.
• To outline strategies for advancing HIV-1 vaccine candidates towards licensure.

Main Methods:

• Analysis of immune correlates of risk from clinical trials.
• Review of emerging vaccine strategies, including improved envelope proteins, DNA, and vector-based approaches.
• Emphasis on eliciting broad and deep immune responses (neutralizing and non-neutralizing antibodies, cell-mediated immunity, mucosal immunity, memory).

Main Results:

• Identification of IgG antibodies to the gp120 V2 loop as correlating with decreased HIV-1 risk.
• Observation that Env-specific IgA antibodies correlate with increased HIV-1 risk.
• Establishment of proof-of-concept efficacy for HIV-1 vaccine candidates.

Conclusions:

• Future HIV-1 vaccine strategies focus on novel immunogens and potent adjuvants to induce diverse immune responses.
• Continued human efficacy trials, integrated with other prevention methods, are essential.
• Sustained international collaboration and funding are vital for successful HIV-1 vaccine licensure.